Biomarkers of clinical transplantation tolerance
Lead Research Organisation:
King's College London
Department Name: Immunology Infection and Inflam Diseases
Abstract
Kidney transplant recipients need to be treated with drugs that hold down the immune system (immunosuppression) for life. These drugs have important side effects and we currently don?t have means to know how much treatment each patient needs.
We have recently defined a series of tests that may allow us to identify which kidney transplant recipients do not reject their grafts when taken off immunosuppression. These are very preliminary results. We need to perform several studies to confirm them.
Thus, we are proposing to repeat the study in new groups of patients. If validated our tests could be used to safely minimise or remove immunosuppression in those kidney transplant recipients that don?t need it.
We have recently defined a series of tests that may allow us to identify which kidney transplant recipients do not reject their grafts when taken off immunosuppression. These are very preliminary results. We need to perform several studies to confirm them.
Thus, we are proposing to repeat the study in new groups of patients. If validated our tests could be used to safely minimise or remove immunosuppression in those kidney transplant recipients that don?t need it.
Technical Summary
Studying a cohort of extremely rare but very informative tolerant kidney transplant recipients we have recently defined a set of biomarkers that can identify them with specificity of 0.964 and sensitivity of 0.933. Using molecular profiling, flow cytometry and IFNgamma; ELISpots we identify patients who have been weaned off all immunosuppression for longer than 1 year and whose kidney function has remained stable. A similar set of biomarkers (B cell expansion and molecular expression) was found by the Immune Tolerance Network (USA) on a similar group of patients.
To translate these tolerance biomarker sets into clinically-useful tools, we propose to test if they are predictive of the tolerant state and if their expression is stable with time. We will do this in collaboration with the US based researchers to achieve a common tolerant biomarker set.
? Hypotheses to test:
? More than 80% of the newly recruited tolerant kidney transplant recipients are positive for the common tolerant biomarker set, compared to less than 20% in control groups.
? Stability of the set of biomarkers of tolerance is maintained in more than 90% of the tolerant patients as long as their function remains stable.
? The expanded B cell numbers detected in both studies reflect an expansion of regulatory B cells in peripheral blood from tolerant kidney transplant recipients.
Methods: An observational cross-sectional study in 3 groups of patients:
? Patient groups:
1.- New set of tolerant kidney transplant recipients from the US and Europe. Control groups: healthy controls, stable patients on triple therapy, stable patients on steroid monotherapy, patients with immunologically driven chronic allograft nephropathy and patients with psoriasis in remission.
2.- All tolerant kidney transplant recipients previously studied to test stability of the signature.
3.- Long term kidney transplant recipients with stable function and patients matched for time post-transplantation with deteriorating function in the last 12 months.
Measurements
? Primary outcome: frequency of patients that display the composite set of biomarkers of tolerance.
? Secondary Outcomes: Patient, graft survival, and biopsy proven acute rejection, independently and as a composite variable, graft function (eGFR, CRT), infection rate, cancer rate, major CV events. To compare between patients positive and negative for the biomarkers of tolerance.
Validation of the common tolerant biomarker set will mean that it could be used as a surrogate end point in clinical trials of transplantation tolerance; this will have substantial implications for the management of transplant patients.
To translate these tolerance biomarker sets into clinically-useful tools, we propose to test if they are predictive of the tolerant state and if their expression is stable with time. We will do this in collaboration with the US based researchers to achieve a common tolerant biomarker set.
? Hypotheses to test:
? More than 80% of the newly recruited tolerant kidney transplant recipients are positive for the common tolerant biomarker set, compared to less than 20% in control groups.
? Stability of the set of biomarkers of tolerance is maintained in more than 90% of the tolerant patients as long as their function remains stable.
? The expanded B cell numbers detected in both studies reflect an expansion of regulatory B cells in peripheral blood from tolerant kidney transplant recipients.
Methods: An observational cross-sectional study in 3 groups of patients:
? Patient groups:
1.- New set of tolerant kidney transplant recipients from the US and Europe. Control groups: healthy controls, stable patients on triple therapy, stable patients on steroid monotherapy, patients with immunologically driven chronic allograft nephropathy and patients with psoriasis in remission.
2.- All tolerant kidney transplant recipients previously studied to test stability of the signature.
3.- Long term kidney transplant recipients with stable function and patients matched for time post-transplantation with deteriorating function in the last 12 months.
Measurements
? Primary outcome: frequency of patients that display the composite set of biomarkers of tolerance.
? Secondary Outcomes: Patient, graft survival, and biopsy proven acute rejection, independently and as a composite variable, graft function (eGFR, CRT), infection rate, cancer rate, major CV events. To compare between patients positive and negative for the biomarkers of tolerance.
Validation of the common tolerant biomarker set will mean that it could be used as a surrogate end point in clinical trials of transplantation tolerance; this will have substantial implications for the management of transplant patients.
Organisations
- King's College London, United Kingdom (Collaboration, Lead Research Organisation)
- University of Edinburgh, United Kingdom (Collaboration)
- Astellas Pharma (Collaboration)
- Uppsala University Hospital (Collaboration)
- University of Hamburg, Germany (Collaboration)
- ALTA (Collaboration)
- King's College Hospital Charitable Trust, United Kingdom (Collaboration)
- NHS Blood and Transplant (NHSBT), Watford, United Kingdom (Collaboration)
- University Hospital Coventry NHS Trust, United Kingdom (Collaboration)
- University of Oxford, United Kingdom (Collaboration)
- University of Regensburg, Germany (Collaboration)
- Oxford University Hospitals NHS Trust, United Kingdom (Collaboration)
- Royal Liverpool and Broadgreen University Hospital NHS Trust (Collaboration)
- Epsom and St Helier University Hospitals NHS Trust (Collaboration)
- Manchester University NHS Foundation Trust, Manchester (Collaboration)
- Genome Identification Diagnostics GmbH (Collaboration)
- Hull and East Yorkshire Hospitals NHS Trust (Collaboration)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (Collaboration)
- University Hospitals of Leicester NHS, United Kingdom (Collaboration)
- University Hospitals Birmingham NHS Foundation Trust, Birmingham (Collaboration)
- Plymouth Hospitals NHS Trust (Collaboration)
- Vall d'Hebron University Hospital (Collaboration)
- Cellogic GmbH (Collaboration)
- Imperial College Healthcare NHS Trust (Collaboration)
- Portsmouth Hospitals NHS Trust (Collaboration)
- Belfast Health and Social Care Trust, Belfast, United Kingdom (Collaboration)
- Institute for Clinical and Experimental Medicine (IKEM) (Collaboration)
- University of Bern (Collaboration)
- Academic Medical Center (Collaboration)
- Great Ormond Street Hospital (GOSH) (Collaboration)
- Royal Free London NHS Foundation Trust, United Kingdom (Collaboration)
- Leeds Teaching Hospitals NHS Trust, United Kingdom (Collaboration)
- BMI The Beaumont Hospital (Collaboration)
- Nantes University Hospital - CHU Nantes (Collaboration)
- Milenia Biotec GmbH (Collaboration)
- Cardiff & Vale University Health Board, United Kingdom (Collaboration)
- Cambridge University Hospitals, Cambridge (Collaboration)
- Evelina London Children's Hospital (Collaboration)
- Nottingham University Hospitals NHS Trust, Nottingham (Collaboration)
- Immunotech S.A.S. (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Barts Health NHS Trust, London (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- Salford Royal NHS Foundation Trust, Greater Manchester (Collaboration)
- St George's Healthcare NHS Trust (Collaboration)
- Guy's and St Thomas' NHS Foundation Trust, London (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- Catalan Health Institute (ICS) (Collaboration)
- University Hospital Regensburg (Collaboration)
- Charité - University of Medicine Berlin (Collaboration)
- East Kent Hospitals University NHS Foundation Trust (Collaboration)
- Sheffield Teaching Hospitals NHS Foundation Trust (Collaboration)
Publications
Afzali B
(2013)
Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation.
in Clinical journal of the American Society of Nephrology : CJASN
Afzali B
(2010)
Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells.
in Clinical and experimental immunology
Afzali B
(2011)
Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells.
in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Bacchetta R
(2014)
Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells.
in Frontiers in immunology
Baron D
(2015)
A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft.
in Kidney international
Bestard O
(2013)
Cross-validation of IFN-? Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients.
in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Canavan JB
(2012)
A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy.
in Blood
Cherukuri A
(2014)
Immunologic human renal allograft injury associates with an altered IL-10/TNF-a expression ratio in regulatory B cells.
in Journal of the American Society of Nephrology : JASN
Cherukuri A
(2012)
An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.
in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
| Description | MSc in Translational Medicine |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Meeting with ANECA & General Director for University Policy about research quality evaluation in Spain |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | BRC Interdisciplinary programme |
| Amount | £500,000 (GBP) |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2009 |
| End | 04/2012 |
| Description | CONICYT - PhD |
| Amount | $135,518 (USD) |
| Funding ID | 72090270, Year 2009 |
| Organisation | National Commission for Scientific and Technological Research (CONICYT) |
| Sector | Public |
| Country | Chile |
| Start | 10/2009 |
| End | 10/2013 |
| Description | European Commission FP7 Health (Bio-DRIM) |
| Amount | £850,000 (GBP) |
| Funding ID | 305147-2 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 11/2012 |
| End | 10/2017 |
| Description | European Commission FP7 Health (The ONE study) |
| Amount | £970,000 (GBP) |
| Funding ID | 260687 |
| Organisation | European Commission |
| Department | Seventh Framework Programme (FP7) |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2011 |
| End | 01/2016 |
| Description | Guy's & St Thomas' Charity |
| Amount | £127,000 (GBP) |
| Funding ID | R090782 |
| Organisation | Guy’s & St Thomas’ Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2010 |
| End | 12/2013 |
| Description | Guy's and St Thomas' Charity |
| Amount | £260,000 (GBP) |
| Funding ID | R080530 |
| Organisation | Guy’s & St Thomas’ Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2009 |
| End | 06/2013 |
| Description | KPA Research support |
| Amount | £17,000 (GBP) |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Department | Guy’s and St Thomas’ Kidney Patients' Association (GSTT KPA) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2011 |
| End | 05/2012 |
| Description | RISET - (Reprogramming the Immune system for the establishment of tolerance). |
| Amount | £10,000,000 (GBP) |
| Funding ID | QLK3-CT-2002-02127 |
| Organisation | Sixth Framework Programme (FP6) |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2003 |
| End | 12/2008 |
| Description | TTS - Mentor Mentee Award |
| Amount | £500 (GBP) |
| Organisation | Transplantation Society |
| Sector | Charity/Non Profit |
| Country | Canada |
| Start | 07/2012 |
| End | 07/2012 |
| Description | WTCCC3 Core Activities: Defining the genetic basis for interactions between donor and recipient DNA that determine early and late renal transplant dysfunction |
| Amount | £127,000 (GBP) |
| Funding ID | 088849/Z/09/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2009 |
| End | 05/2012 |
| Title | GAMBIT cell and mRNA collection |
| Description | cells mRNA from blood serum urine mRNA fresh urine |
| Type Of Material | Database/Collection of Data/Biological Samples |
| Provided To Others? | No |
| Impact | Future biomarkers of tolerance to be developed. |
| Title | NIHR-HIC |
| Description | Integration of anonimysed clinical data and "omics" for research and clinical purposes |
| Type Of Material | Database/Collection of data |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | Not yet. It will facilitate research and clinical practice in a large scale |
| URL | http://www.nihr.ac.uk/about/hic.htm |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | ALTA |
| Department | Research and Development in Biotechnology |
| Country | Italy |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Academic Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Astellas Pharma |
| Country | Japan |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Bristol-Myers Squibb |
| Country | United States |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Catalan Health Institute (ICS) |
| Department | University Hospital of Bellvitge (HUB) |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Cellogic GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Charité - University of Medicine Berlin |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Genome Identification Diagnostics GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Immunotech S.A.S. |
| Country | France |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Institute for Clinical and Experimental Medicine (IKEM) |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | Milenia Biotec GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | University Hospital of Nantes |
| Country | France |
| Sector | Hospitals |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | University of Hamburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | BIO-DrIM. FP7 - Consortium |
| Organisation | University of Regensburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies. |
| Collaborator Contribution | The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups. |
| Impact | None published yet |
| Start Year | 2011 |
| Description | GAMBIT consortium |
| Organisation | Cardiff and Vale University Health Board |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | East Kent Hospitals University NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Evelina London Children's Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Great Ormond Street Hospital (GOSH) |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Department | Transplant Unit |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Hull and East Yorkshire Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Institute for Clinical and Experimental Medicine (IKEM) |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | King's College Hospital NHS Foundation Trust (NCH) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Manchester University NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Portsmouth Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Royal Free London NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Salford Royal NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Sheffield Teaching Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | St George's Healthcare NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | University Hospitals of Leicester NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Uppsala University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | GAMBIT consortium |
| Organisation | Vall d'Hebron University Hospital |
| Department | Renal Unit |
| Country | Israel |
| Sector | Hospitals |
| PI Contribution | I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research. |
| Collaborator Contribution | - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design. |
| Impact | Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67. |
| Start Year | 2009 |
| Description | The ONE study - FP7 Consortium |
| Organisation | University Hospital Regensburg |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | Use of regulatory Tregs for the induction of tolerance in renal transplant patients. |
| Collaborator Contribution | Use of different cell type with the aim to induce tolerance in renal transplant patients. |
| Impact | Few manuscripts submitted. |
| Start Year | 2010 |
| Description | The ONE study - FP7 Consortium |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Use of regulatory Tregs for the induction of tolerance in renal transplant patients. |
| Collaborator Contribution | Use of different cell type with the aim to induce tolerance in renal transplant patients. |
| Impact | Few manuscripts submitted. |
| Start Year | 2010 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | BMI The Beaumont Hospital |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Barts Health NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Belfast Health and Social Care Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Cambridge University Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Cardiff and Vale University Health Board |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Epsom and St Helier University Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Imperial College Healthcare NHS Trust |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Manchester University NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | NHS Blood and Transplant (NHSBT) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Nottingham University Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Plymouth Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Portsmouth Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Royal Free London NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Royal Liverpool and Broadgreen University Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | Sheffield Teaching Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | St George's Healthcare NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | University Hospitals Birmingham NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | University Hospitals Coventry and Warwickshire NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | University Hospitals of Leicester NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Description | UK and Ireland Renal Transplant Consortium (UKIRTC) |
| Organisation | University of Edinburgh |
| Department | University Court |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Project Lead Management Contract of workers Coordination of samples Driving analysis Funding Driving publication |
| Collaborator Contribution | Sample collection Data collection Sanger: performed chips and analysis of data, significant input in publication consortium ideas for developments |
| Impact | Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&view=article&id=26&Itemid=140 Publications: 1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115 Conference communication in British Transplantation Society, March 2013. Bornemouth, UK |
| Start Year | 2009 |
| Title | Method of Determining Tolerance |
| Description | A method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers. The patent application PCT/GB2011/050874, priority date 4 May 2010, entitled "Method of Determining Tolerance", will enter National Phase prosecution on 4 November 2012. Assignees: King's College London, Charité - Universitätsmedizin Berlin, Miltenyi Biotec GmbH Inventors: Maria Hernandez Fuentes, Irene Rebollo Mesa, Birgit Sawitski, Hans-Dieter Volk, Uwe Janssen, Stefan Tomiuk |
| IP Reference | WO2011138609 |
| Protection | Patent application published |
| Year Protection Granted | 2012 |
| Licensed | Commercial In Confidence |
| Impact | A method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers. |
| Title | A method for evaluating transplantation tolerance |
| Description | Diagnostic Test to identify tolerance in kidney transplant recipients. We are developing the application strategy for patients. Needs a biomarker-led clinical trial that has not been funded yet. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2013 |
| Development Status | On hold |
| Impact | If the clinical trial shows clinical benefit for the patients who are in the biomarker-led group, we will have a tool to personalise the post-transplant management of a set of patients (5 - 15%) that will mean less immunosuppression, with the lower rate of secondary events this has and better quality of life. |
| Description | Active participation in "Science Week" Instituto Caniada Blanch, Portobello, London |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Around 40 students attended two sessions in the school where we explained how to conduct a clinical trial and what questions can be answered with this. Also what ethical implications the set up and pariticipation in a clinical trial arises. |
| Year(s) Of Engagement Activity | 2016 |
| Description | BRC PPI event for GAMBIT and DECISIONS |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | ? n/a |
| Year(s) Of Engagement Activity | 2014 |
| Description | Chair, Women and Science Roundtable |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Organised by The Office for Cultural and Scientific Affairs of the Embassy of Spain (OCSA) and SRUK/CERU Part1: http://vimeo.com/98850732 . Part 2: http://vimeo.com/99146100 |
| Year(s) Of Engagement Activity | 2014 |
| Description | Channel 4 news |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Discussions of immune tolerance with Channel 4 news, which was published as an article and featured on the news in May 2010 Gained exposure of the biomarkers of tolerance to Channel 4 news which a subsequent article published |
| Year(s) Of Engagement Activity | 2010 |
| Description | Conference on Research & Innovation for the Development & Growth |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Regional |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Attended the Conference on Research & Innovation for the Development & Growth, organized by "Europa en Suma", Madrid Programme in Spanish: http://europaensuma.org/la-europa-excelente-innovacion-e-investigacion Short video of my contribution (in Spanish) : http://www.europaensuma.org/videos-jornada/vervideo/17/jornada-la-europa-excelente/la-europa-excelente-ponente-maria-hernandez-fuentes I was asked to do an interview on a TV programme for to discuss the future of science in Spain. This has contributed to dissemination of science to the general public. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://europaensuma.org/la-europa-excelente-innovacion-e-investigacion |
| Description | Dr Hernandez-Fuentes participates in an online radio programme, Naukas www.naukas.com, |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Discussion about brain drain and brain gain and how to maximise the benefit of "scientist on the move" |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://naukas.com/2015/04/07/15a-tertulia-media2ciencia-ciencia-lejos-de-espana/ |
| Description | Dr Hernandez-Fuentes with Dr Rebollo-Mesa actively participate in "Science Week" Instituto Caniada Blanch, Portobello, London |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | We explained how a clinical trial works by actively participating in a trial testing different breakfasts. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Dr Maria Hernandez-Fuentes, appeared in a radio programme based in Toledo, Spain,"LUCIERNAGAS - CIENCIA AL DIA" |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | I explained aims of the society Spanish Researchers in the UK and about transplantation science |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://ciencia-luciernagas.blogspot.com.es/2015/04/srukceru-sociedadcientificos-espanoles.html |
| Description | Dr María Hernández-Fuentes appeared in channel "La Sexta", program: Constantes y Vitales, Spain |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview to talk about the differences in the situation of science and scientists between Spain and UK |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.lasexta.com/constantes-vitales/noticias/investigadores-insisten-que-ciencia-puede-ser-mot... |
| Description | Europa 2013 |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Appeared in RTVE to talk about the differences we observed in science culture between the UK and Spanish societies: minute 25:26 Public dissemination of science culture. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.rtve.es/alacarta/videos/europa/europa-2013-27-09-13/2034251/ |
| Description | GAMBIT - DECISION Patient information event |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | On the We reported to participants the main results for the main results of the study funded by the MRC award - with the help of the added funding - the study is called "GAMBIT" but also the social science part of the study DECISIONS. Participants were very grateful that we have done the effort of communicating the results and tell them about the plans for the projects. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.kcl.ac.uk/lsm/research/divisions/timb/research/tolerance/gambit/index.aspx |
| Description | Hispan TV La Gran Historia - Donación de órganos en Uruguay |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | I discussed the benefits of transplantation for society and the importance in Research in this field |
| Year(s) Of Engagement Activity | 2007,2014 |
| Description | Kidney Patient Association website |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | An online article of the GAMBIT study on KPA website. Disseminated the brief summary of the GAMBIT study to patients and public. |
| Year(s) Of Engagement Activity | 2013 |
| Description | King's College London |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Discussions of immune tolerance with King's College London, which was published as an article and featured on the news on 25th May 2010 Gained exposure of the biomarkers of tolerance to King's College London which a subsequent article published |
| Year(s) Of Engagement Activity | 2010 |
| Description | Lecture in Science week at Instituto Canada Blanch |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Lecture in Science week at Instituto Canada Blanch (Spanish Primary & Secondary School ). http://monix.a.tripod.com/spanish_school_london/welcome.html 29 May 2012 Title of lecture: What is a clinical Trial? 10 May 2013 Title: Transplantation: History and ethical issues This has contributed to dissemination of science to the general public. School has asked for a visit next year, which we will do. |
| Year(s) Of Engagement Activity | 2012,2013 |
| URL | http://www.sruk.org.uk/documents/press-releases/130430-SRUKScienceWeek-Eng.pdf |
| Description | MRC Centenary Event - Panel Debate - The Future of Transplantation 20 June 2013 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Prof Lechler was the Panel member for panel discussion in MRC centre transplantation which covered the following topics: 1. Addressing and overcoming organ shortage in the UK - specifically, how can research help? 2. The use of stem cells for organ repair and replacement 3. The use of genetics research and individual genetic profiling ('barcodes') to predict transplant outcome 4. Public health, personal risk; the role of patient participation in experimental (transplant) medicine Provided the opportunity to engage public to deepen their understanding of transplantation science. |
| Year(s) Of Engagement Activity | 2013 |
| Description | Media Interest (SRUK) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | María Hernández Fuentes, vice-president of SRUK/CERU talks about the brain drain happening in Spain and the difficulties that emigrated scientists face when trying to return. no known |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.zoomnews.es/105358/actualidad/mundo/cientificos-espanoles-extranjero-ven-cada-dia-mas-dif... |
| Description | Nature |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Nature mentioned SRUK as one of the networking organisations of scientists in the UK This has contributed to dissemination of science to the general public. |
| Year(s) Of Engagement Activity | 2012 |
| URL | http://www.sruk.org.uk/documents/on-the-media/20121122-Nature%20Jobs.pdf |
| Description | New Scientist |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Discussions of immune tolerance with the New Scientist, regarding an idea of an article for organ transplantation Gained exposure of the biomarkers of tolerance to the New Scientist |
| Year(s) Of Engagement Activity | 2010 |
| Description | RTVE interview |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Dr María Hernández-Fuentes appeared in RTVE to talk about the differences we observed in science culture between the UK and Spanish societies no known |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.rtve.es/alacarta/videos/europa/europa-2013-27-09-13/2034251 |
| Description | Reuters |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Discussions of immune tolerance with the Reuters news agency, which was published as an article on 25th May 2010 Gained exposure of the biomarkers of tolerance to the Reuters news agency which a subsequent article published |
| Year(s) Of Engagement Activity | 2010 |
| Description | STEM Ambassador visit |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | STEM Ambassador visit. "Meet the professional session" for sixth form students before they choose their chosen subject in the university. I gave a talk about my own career choice and steps that I took to become a scientist. There was a session of questions and answers on different future possibilities. This has contributed to dissemination of science to the general public/students. Expected impacts on student subject choice and enhanced their understanding of career path as a scientist. |
| Year(s) Of Engagement Activity | 2012 |
| URL | http://www.inspiringfutures.org.uk |
| Description | Science week Instituto Canada Blanch |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | talk sparked questions and discussion ignited interest in students |
| Year(s) Of Engagement Activity | 2014 |
| Description | Spanish Embassy in London celebrates a Seminar on Science Diplomacy |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | This seminar raised great expectation among the diplomatic community in London, and between academic and scientific institutions, which was attended by a large representation of these sectors. The seminar had two main objectives: to have a good knowledge of the best practices of scientific diplomacy carried out by leading countries in research and innovation but also in developing nations. The other aim was to identify the most favourable opportunities for scientific mobility |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.spainculturescience.co.uk/es/noticias/la-embajada-de-espa%C3%B1a-en-londres-organiza-un-s... |
| Description | Team Participation in Clinical Trials Day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Open day to explain active clinical trials in the Division of Transplantation at Guy's Hospital |
| Year(s) Of Engagement Activity | 2015 |
| Description | The Telegraph |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Discussions of immune tolerance with the The Telegraph, which was published as an article on 26th May 2010 Gained exposure of the biomarkers of tolerance to the The Telegraph which a subsequent article published |
| Year(s) Of Engagement Activity | 2010 |
| Description | Transplantation Morning 19/05/15 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | A number of patients stopped at the stand where we were explaining current research studies they could participate on, whether observational or clinical trials |
| Year(s) Of Engagement Activity | 2015 |
| Description | Transplantation-tolerance website |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | This website updates participants, physicians and the general public of the progress in the project. A small number of patients have seen this and other websites about transplantation-tolerance and have contacted the PI subsequently. |
| Year(s) Of Engagement Activity | 2010,2011 |
| Description | Vice President of Society of Spanish Researchers in the United Kingdom |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Acting as a Vice President of the Society to: a) Create a social network of researchers and students working in the UK b) Increase social awareness of R&D in the Spanish and British societies c) Represent its membership before Spanish and British Institutions and media d) Establish collaborations between Spanish and British Institutions On 2 occasions I have met with high officials in the Departments of Education and Industry from Spain (where science is embedded) and discussed possible evaluation systems for scientists. Possibly influencing policy in the evaluation framework to be set up in the future in Spain. SRUK keeps a diverse programme of public engagement activities in the UK that are contributing to the general understanding of science. |
| Year(s) Of Engagement Activity | 2012,2013 |
| URL | http://www.sruk.org.uk |
| Description | Zoomnews |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | talked about the brain drain happening in Spain and the difficulties that emigrated scientists face when trying to return. This has contributed to dissemination of science to the general public. |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.zoomnews.es/105358/actualidad/mundo/cientificos-espanoles-extranjero-ven-cada-dia-mas-dif... |